These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32620606)

  • 1. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
    Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
    Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.
    Caruso JA; Campana R; Wei C; Su CH; Hanks AM; Bornmann WG; Keyomarsi K
    Cell Cycle; 2014; 13(16):2587-99. PubMed ID: 25486199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
    Stark K; Burger A; Wu J; Shelton P; Polin L; Li J
    PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
    Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
    Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells.
    Sundar SN; Kerekatte V; Equinozio CN; Doan VB; Bjeldanes LF; Firestone GL
    Mol Endocrinol; 2006 Dec; 20(12):3070-82. PubMed ID: 16901971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
    de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
    Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines.
    De Santi M; Galluzzi L; Lucarini S; Paoletti MF; Fraternale A; Duranti A; De Marco C; Fanelli M; Zaffaroni N; Brandi G; Magnani M
    Breast Cancer Res; 2011 Mar; 13(2):R33. PubMed ID: 21435243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
    Salahuddin A; Ghanem H; Omran GA; Helmy MW
    Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    Hinsche O; Girgert R; Emons G; Gründker C
    Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy.
    Ramadan WS; Alseksek RK; Mouffak S; Talaat IM; Saber-Ayad MM; Menon V; Ilce BY; El-Awady R
    Eur J Pharmacol; 2024 Nov; 983():177001. PubMed ID: 39284403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).
    Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.
    Sulaiman A; Sulaiman B; Khouri L; McGarry S; Nessim C; Arnaout A; Li X; Addison C; Dimitroulakos J; Wang L
    FEBS Lett; 2016 Dec; 590(24):4606-4616. PubMed ID: 27859250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.